Allogeneic cellular gene therapy in hemoglobinopathies—evaluation of hematopoietic SCT in sickle cel...
Allogeneic cellular gene therapy in hemoglobinopathies—evaluation of hematopoietic SCT in sickle cell anemia
About this item
Full title
Author / Creator
Lucarelli, G , Gaziev, J , Isgrò, A , Sodani, P , Paciaroni, K , Alfieri, C , De Angelis, G , Marziali, M , Simone, M D , Gallucci, C , Roveda, A , Saltarelli, F , Torelli, F and Andreani, M
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Many patients with thalassemia have been cured with BMT since the first successful transplant in 1981. Allogeneic stem cell gene therapy is the only treatment option for patients with sickle cell anemia (SCA). A total of 11 patients with a median age of 12 years (range, 2–16), affected by SCA, received hematopoietic SCT from HLA-identical, related...
Alternative Titles
Full title
Allogeneic cellular gene therapy in hemoglobinopathies—evaluation of hematopoietic SCT in sickle cell anemia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_968170606
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_968170606
Other Identifiers
ISSN
0268-3369
E-ISSN
1476-5365
DOI
10.1038/bmt.2011.79
